Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,500
Employees7,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,500
Employees7,500

BIIB Key Statistics

Market cap
26.26B
Market cap26.26B
Price-Earnings ratio
20.36
Price-Earnings ratio20.36
Dividend yield
Dividend yield
Average volume
1.61M
Average volume1.61M
High today
$181.77
High today$181.77
Low today
$177.45
Low today$177.45
Open price
$177.71
Open price$177.71
Volume
1.55M
Volume1.55M
52 Week high
$202.41
52 Week high$202.41
52 Week low
$114.66
52 Week low$114.66

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $178.96. The company's market cap stands at 26.26B, with a P/E ratio of 20.36.

As of 2026-04-15, Biogen(BIIB) stock has fluctuated between $177.45 and $181.77. The current price stands at $178.96, placing the stock +0.9% above today's low and -1.5% off the high.

The Biogen(BIIB)'s current trading volume is 1.55M, compared to an average daily volume of 1.61M.

In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $114.66.

In the last year, Biogen(BIIB) shares hit a 52-week high of $202.41 and a 52-week low of $114.66.

BIIB News

TipRanks 1d
Biogen upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Biogen (BIIB) to Overweight from Neutral with a price target of $214, up from $177. The company’s acquisition of Apellis Pharmaceuticals...

Simply Wall St 5d
Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Biogen and Alloy Therapeutics have entered a new collaboration to develop multi target antisense oligonucleotide drugs using Alloy’s AntiClastic ASO platform....

Biogen’s Alloy Antisense Deal Adds New Dimension To Genetic Medicine Bet

Analyst ratings

47%

of 36 ratings
Buy
47.2%
Hold
47.2%
Sell
5.6%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.